- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Chris Claiborne, Millennium
S
Chris Claiborne
Senior Director, Oncology Chemistry, Millennium
BIGGEST HIT: 5 NMEs into trials in 3 years
KEY ROLE IN: Millennium's $8.8 billion Takeda payday
Already a rising star in grad school, Chris Claiborne spent seven years "in training" with Merck's discovery corps before jumping in 2002 to Millennium, then a promising startup in the Boston biocluster.
Chris Claiborne
Six years later, Claiborne, 40, has major bragging rights: five first-in-class compounds moved into trials in three years—including Velcade. "That was the first time I had to advocate for something transforming for the company—but knowing it might fail," he recalls. "Having the organization believe in my arguments transformed my interest in working in biotech."
If leading the preclinical lab has been a learning curve, Claiborne has proved a quick study—and all the credit goes to his boss, Chief Scientific Officer Joseph Bolen, he insists. "He has always emphasized the importance of culture among the scientists and spends every Friday in the lab." Drug discovery is certainly a team effort, but the entire industry took note of Claiborne's stunning six-year run when, last April, Takeda bought the biotech for a sweet $8.8 billion.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.
